Online inquiry

IVTScrip™ mRNA-Anti-C5, LFG 316(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10261MR)

This product GTTS-WQ10261MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets C5 gene. The antibody can be applied in Choroiditis, Age-related macular degeneration (AMD) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001317163.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 727
UniProt ID P01031
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-C5, LFG 316(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ10261MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ1951MR IVTScrip™ mRNA-Anti-SLITRK6, AGS15C(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AGS15C
GTTS-WQ3037MR IVTScrip™ mRNA-Anti-PTK7, Anti-PTK7 ADC(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA Anti-PTK7 ADC
GTTS-WQ7772MR IVTScrip™ mRNA-Anti-MMP9, GS-5745(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA GS-5745
GTTS-WQ1916MR IVTScrip™ mRNA-Anti-VEGFA, AGN 150998(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AGN 150998
GTTS-WQ7703MR IVTScrip™ mRNA-Anti-ERBB2, GEXMab73(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA GEXMab73
GTTS-WQ15279MR IVTScrip™ mRNA-Anti-EGFR, Theraloc(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA Theraloc
GTTS-WQ11828MR IVTScrip™ mRNA-Anti-LAG3, MK-4280(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MK-4280
GTTS-WQ15950MR IVTScrip™ mRNA-Anti-NGF, ZTS-00508841(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ZTS-00508841
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.